Clinical Trial Update: Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial NCT02331875 investigating IPH2201 for oral squamous cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Squamous Cell Carcinoma

Drugs mentioned

• IPH2201

Snippet

Sponsor: Innate Pharma | Conditions: Squamous Cell Carcinoma of the Oral Cavity | Phase 1, Phase 2 | Status: TERMINATED